No Data
No Data
No Data
No Data
No Data
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Dow JonesApr 11 16:23 ET
Promising Preclinical Alzheimer's Candidate and Diverse Pipeline Bolster Hoth Therapeutics' Buy Rating
TipRanksApr 5 06:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
Moomoo 24/7Apr 5 06:15 ET
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Dow JonesApr 2 09:13 ET
Express News | EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
Moomoo 24/7Apr 2 09:03 ET
Hoth Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 400% EF Hutton $6.5 → $7 Maintains Buy 02/05/2024 185.71% HC Wainwright & Co. → $4 Initiates Co
BenzingaApr 2 09:01 ET
No Data
No Data